Merck (MRK) PT Raised to $74 at JPMorgan

JPMorgan raised its price target on Merck (NYSE: MRK) to $74.00 (from $72.00) while maintaining a Overweight rating.

Analyst Chris Schott remains positive on the equity and sees further potential for Keytruda to generate upside through 2018 and into 2019 citing both the ramp in lung along with data in other tumor types. The analyst is now forecasting Keytruda sales of $6.5 billion in 2018 and raises his 2019/2020 sales forecasts to $8.0 billion & $12 billion respectively.

You May Also Be Interested In

• Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
• Viking Therapeutic (VKTX) PT Raised to $87 at Truist Securities
• Philip Morris (PM) PT Raised to $193 at UBS, Neutral Rating Maintained